Home HOME Neoplasma 2022 Neoplasma Vol.69, No.2, p.430–442, 2022

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.2, p.430–442, 2022

Title: Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases
Author: Jovana Despotović, Aleksandar Bogdanović, Sandra Dragičević, Danijel Galun, Zoran Krivokapić, Aleksandra Nikolić

Abstract: This study aimed to examine the expression pattern of tumoral and circulating miR-93-5p in patients with colorectal cancer (CRC) liver metastasis (CRLM) and to explore its predictive and prognostic potential. CRLM tissue, surrounding non-tumor liver tissue, and serum were obtained from 35 patients with CRLM. The expression pattern of tissue and circulating miR-93-5p in patients with CRLM was determined using quantitative polymerase chain reaction, using miR-16-5p for normalization. Sample-based cut-off values for CRLM and serum miR-93-5p expression were calculated using Receiver Operating Characteristic curve analysis to stratify the patients into high and low miR-93-5p expression groups which were that compared with patients’ clinicopathological data, therapy response, one-year disease-free survival, and disease recurrence. Relative miR-93-5p expression was higher in CRLM in comparison to the non-metastatic liver tissue (p < 0.001). CRLM miR-93-5p expression showed moderate negative correlation with carcinoembryonic antigen levels (r = -0.406; p = 0.016).
There were no differences in high-/low-miR-93-5p expression and therapy responders vs. non-responders, which was confirmed in vitro using metastatic and normal colonic cells SW620 and HCEC-1CT, respectively. No difference was observed in one-year recurrence-free survival in patients with high vs. low miR-93-5p expression in CRLM or serum. However, high miR-93-5p serum levels were significantly associated with early disease recurrence (p = 0.035). In conclusion, miR-93-5p serum levels could be potentially used as a prognostic factor for early disease recurrence in CRLM patients.

Keywords: metastatic colorectal cancer; colorectal cancer liver metastasis; microRNA; miR-93-5p; prognostic biomarker
Published online: 17-Jan-2022
Year: 2022, Volume: 69, Issue: 2 Page From: 430, Page To: 442
Price: 27.30 €

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.